ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 145 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.60 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $9,458 | +61.0% | 912 | +25.6% | 0.00% | – |
| Q1 2023 | $5,874 | – | 726 | +764.3% | 0.00% | – |
| Q1 2020 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q4 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q3 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q2 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q1 2019 | $0 | – | 84 | 0.0% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 84 | 0.0% | 0.00% | – |
| Q3 2018 | $2,000 | -99.0% | 84 | -99.2% | 0.00% | – |
| Q2 2018 | $199,000 | +40.1% | 9,903 | +22.7% | 0.00% | – |
| Q1 2018 | $142,000 | -28.3% | 8,068 | +0.0% | 0.00% | – |
| Q4 2017 | $198,000 | -2.9% | 8,066 | +2.1% | 0.00% | – |
| Q3 2017 | $204,000 | -18.4% | 7,900 | -14.3% | 0.00% | – |
| Q2 2017 | $250,000 | +14.7% | 9,220 | +26.0% | 0.00% | – |
| Q1 2017 | $218,000 | +73.0% | 7,320 | +57.8% | 0.00% | – |
| Q4 2016 | $126,000 | – | 4,640 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |